These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15518769)

  • 1. Does mycophenolate mofetil increase the incidence of infections in stable renal transplant recipients initially treated with a two-drug regimen?
    Chen Y; Chu SH; Wei TY; Yen TH; Chiang YJ; Wu CT; Chen HW
    Transplant Proc; 2004 Sep; 36(7):2122-3. PubMed ID: 15518769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients?
    Prokopenko E; Scherbakova E; Vatazin A; Pasov S; Budnikova N; Agafonova S
    Drugs Exp Clin Res; 2005; 31(5-6):199-205. PubMed ID: 16425976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infectious complications in using mofetil micofenolate in patients with renal allotransplant].
    Prokopenko EI; Shcherbakova EO; Vatazin AV; Kruglov EE; Pasov SA; Budnikova NE; Agafonova SG; Rusanova EV
    Ter Arkh; 2005; 77(1):67-72. PubMed ID: 15759459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
    Satoh S; Tada H; Murakami M; Tsuchiya N; Inoue T; Togashi H; Matsuura S; Hayase Y; Suzuki T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1751-3. PubMed ID: 15919454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
    Tsai MK; Hu RH; Lee CJ; Lee PH
    J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression.
    Bernabeu-Wittel M; Naranjo M; Cisneros JM; Cañas E; Gentil MA; Algarra G; Pereira P; González-Roncero FJ; de Alarcón A; Pachón J
    Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):173-80. PubMed ID: 11957018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols.
    Meier-Kriesche HU; Friedman G; Jacobs M; Mulgaonkar S; Vaghela M; Kaplan B
    Transplantation; 1999 Nov; 68(10):1496-502. PubMed ID: 10589946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
    Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
    Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?
    Johnson DW; Nicol DL; Purdie DM; Preston JM; Brown AM; Hawley CM; Campbell SB; Wall D; Griffin AD; Isbel NM
    Transplantation; 2002 Apr; 73(7):1158-63. PubMed ID: 11965051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.